Navigation Links
Vestara and EXP Pharmaceutical Services Corp. Announce Partnership Making Available Industry's Only Automated Pharmaceutical Waste Management Solution to over 5,000 U.S. Hospitals
Date:2/16/2010

Vestara, the healthcare industry's only provider of automated pharmaceutical waste management solutions, announced a strategic partnership with EXP Pharmaceutical Services Corp., the nation's premier pharmaceutical returns and pharmacy services company.

Irvine, CA (PRWEB) February 16, 2010 -- Vestara, the healthcare industry's only provider of automated pharmaceutical waste management solutions, announced a strategic partnership with EXP Pharmaceutical Services Corp., the nation's premier pharmaceutical returns and pharmacy services company.

The Vestara-EXP partnership stems from both companies' recognition of the industry's need for an effective solution that will allow healthcare entities to properly manage pharmaceutical waste and play a key role in helping to preserve the environment.

"EXP has seen the increasing need of a turnkey solution for easily and compliantly managing pharmaceutical waste in U.S. hospitals. Vestara's EcoRex® addresses that need, and we are very excited to offer a solution that will empower our clients to help preserve the environment, be compliant, and cut costs," said Kirk Herweck, EXP's Director of National Accounts and Business Development.

Through this partnership, EXP's current and future clientele will be offered market-leading pricing and service for Vestara's EcoRex, the industry's only, and patented, Automated Pharmaceutical Waste Management Solution. This make-sense solution automates the pharmaceutical waste management and sorting process, while providing data tracking with a manifest for every piece of pharmaceutical waste that is disposed.

EXP serves 70% of the U.S. hospital-based Reverse Distribution Market, represented by over 5,000 hospital customers. In addition to its well-established market dominance, EXP also has one of the most experienced regulatory-compliance staffs in the industry. EXP will actively offer and provide details of the Vestara solution in each of its client consultations, going forward.

"EXP's market leadership is a key component to this partnership. Instantly, Vestara's Pharmaceutical Waste Management Solution is available to over 70% of U.S. hospitals. We applaud EXP for taking a stand in providing to their customers an effective tool in defense of the environment," said Jon D. Holder, Vestara's Vice President of Business Development.    

Vestara's EcoRex Automated Pharmaceutical Waste Management System utilizes barcode technology already widely used in hospitals to track drug utilization that prevents medication errors through a proprietary, continuously-updated database of more than 180,000 National Drug Code (NDC) products, to instantly categorize pharmaceutical waste at time of presentation. By automating the identification and sorting of different types of residual drugs, empty containers, and each hospital's unique admixtures, EcoRex® eliminates the human error and potential cross contamination inherent in manual sorting of pharmaceutical waste reducing the negative impact on the environment. Just as important, relevant data and an audit trail are provided in the form of comprehensive reports for client records.

For further information about the Vestara-EXP partnership and its products and services, please call 877-937-4397 or email rxwaste(at)expworld(dot)com.

About Vestara
Vestara, headquartered in Irvine, CA, provides proprietary technology to automatically identify, sort, and segregate hazardous and non-hazardous pharmaceutical waste into proper waste streams. Vestara's solutions not only assure clients will be compliant with all federal and state laws, but that they will experience a more efficient health system workforce and true cost savings in managing pharmaceutical waste. Most importantly, clients will play a critical role in preserving our precious environment. To learn more, please visit www.vestara.com.

About EXP Pharmaceutical Services Corp.
EXP Pharmaceutical Services Corp. provides reverse distribution services for the return and destruction of expired and unwanted pharmaceuticals. EXP is a leading member of the pharmaceutical reverse distribution industry specializing in product returns processing and other pharmacy services such as physical inventory and end-to end recall solutions. To learn more, please visit www.expworld.com.

# # #

Read the full story at http://www.prweb.com/releases/2010/02/prweb3599344.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Vestara Announces Agreement with Leading Environmental "Champion for Change" Company Amerinet
2. Vestara and MedClean Technologies Announce Co-Marketing Partnership to Expand Innovative Solution for Pharmaceutical Waste Management
3. Vestara Joins National Health Organization Practice Greenhealth to Further Support Environmental Practices
4. Vestara Awarded MedAssets Supplier Contract For Automated Pharmaceutical Waste Management Solution
5. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
10. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... , ... Harbour , a DAO (decentralized autonomous organization) that harnesses the ... their technical specifications . , 2017 has seen an explosion of token launches ... which offerings will garner the greatest ROI. Dean Eigenmann, Co-founder and CEO of Harbour, ...
(Date:6/27/2017)... , ... June 27, 2017 , ... A January 18th ... projected to reach a staggering $6.81 billion by the year 2024 according to a ... a faster rate than those made from titanium. Los Angeles area clinic Beverly Hills ...
(Date:6/27/2017)... ... June 27, 2017 , ... Drs. Gregory Toback and ... in Mystic, CT. Covering the process and maintenance strategies of gum grafting and ... periodontal procedures. Drs. Toback and Urbanski practice as experienced periodontists in ...
(Date:6/27/2017)... Los Angeles, CA (PRWEB) , ... June 27, 2017 , ... ... on what crooked bites can indicate about early life experiences. What happens to a ... study reveals that stresses after birth can also take a toll on a baby’s ...
(Date:6/26/2017)... ... June 26, 2017 , ... The Centers for Advanced Orthopaedics ... of Richard Robinson as chief operating officer (COO). In this role, Robinson brings ... track record of simplifying business processes and developing growth strategies to increase market ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... , June 9, 2017 AirXpanders, Inc. (ASX: ... on the design, manufacture, sale and distribution of the ... the progress of its commercial roll-out in ... in more than one hundred (100) medical institutions and ... AeroForm offers a needle-free alternative for women who choose ...
(Date:6/7/2017)... , June 7, 2017 Endo International ... June 7, 2017, the Hon. Joseph R. Goodwin ... of West Virginia , entered a ... Inc. Pelvic Repair System Products Liability Litigation (the "MDL") ... MDL cases to provide expert disclosures on specific causation ...
(Date:6/3/2017)... 3, 2017  Eli Lilly and Company (NYSE: ... from the Phase 3 MONARCH 2 study showed ... inhibitor, in combination with fulvestrant, significantly improved progression-free ... in women with hormone-receptor-positive (HR+), human epidermal growth ... have relapsed or progressed after endocrine therapy (median ...
Breaking Medicine Technology: